Childhood tuberculosis.
| Autor: | Cameron LH; Department of Pediatrics, Sections of Infectious Diseases., Cruz AT; Department of Pediatrics, Sections of Infectious Diseases.; Emergency Medicine, Baylor College of Medicine, Houston, Texas, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current opinion in infectious diseases [Curr Opin Infect Dis] 2022 Oct 01; Vol. 35 (5), pp. 477-483. Date of Electronic Publication: 2022 Aug 10. |
| DOI: | 10.1097/QCO.0000000000000866 |
| Abstrakt: | Purpose of Review: We discuss the most recent literature to support the identification of children at risk for tuberculosis and optimal testing and treatment strategies. Recent Findings: The identification and management of children with tuberculosis has increased in complexity due to the recent severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic, greater use of immunosuppressive agents, and the administration of shorter, rifamycin-containing treatment regimens. Advancements in the diagnosis and treatment of tuberculosis in children include: use of interferon gamma release assays (IGRAs); molecular-based tests; and shorter courses of treatment. While the essential steps to identify and treat children at risk for tuberculosis remain unchanged, providers must be aware of impact of these challenges. Summary: The SARS-CoV-2 pandemic will likely have a negative impact on global tuberculosis control. It is important that countries maintain a comprehensive approach to the identification and management of children at risk for tuberculosis. Increasing evidence supports enhanced utilization of IGRAs and molecular-based testing to improve the diagnosis of tuberculosis in children. Shorter course, rifamycin-based treatment regimens are available to treat children with tuberculosis infection; however, their use is limited in some immunosuppressed children due to drug-drug interactions. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|